Physician

Gustavo P Morel, MD

According to 2025 Medicare claims, Gustavo Morel, MD (NPI: 1104855030) practices hematology, with the plurality of this provider's patient population coming from Dickinson, MI. This provider's primary affiliated billing organization is DICKINSON COUNTY HEALTHCARE SYSTEM (NPI: 1891751186; TIN: 382780429) and primary practice location at 49801-3650. Morel is affiliated with the OSF Healthcare System (ACO ID: A3289) and AdvantagePoint Health Alliance - Great Lakes, LLC (ACO ID: A4652), participating under the MSSP model.

Morel's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 370 traditional Medicare patients, billed 801 HCPCS/CPT codes, and received $59,755 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,880 prescription claims across 322 beneficiaries totaling $6,237,890 in drug costs, led by Erleada (Apalutamide). DME data shows 11 claims. Open Payments data shows 69 records totaling $1,528. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $109,214 to $59,755. In contrast, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,212,625 to $6,237,890. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $15,060 to $3,604.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	560	2,884	$109,214
2016	509	1,216	$72,449
2017	483	1,116	$73,012
2018	468	1,265	$61,773
2019	505	2,145	$78,851
2020	420	1,101	$63,543
2021	380	1,566	$75,918
2022	377	1,811	$65,575
2023	352	745	$58,066
2024	370	801	$59,755

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	243	1,398	$1,212,625
2016	271	1,859	$2,165,685
2017	256	1,601	$2,791,733
2018	250	1,653	$3,845,920
2019	289	1,897	$4,545,177
2020	301	1,944	$3,803,381
2021	297	1,992	$3,283,286
2022	302	1,994	$4,169,527
2023	307	1,927	$4,794,274
2024	322	1,880	$6,237,890

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	142	$14,656
2016	N/R	62	$2,792
2017	N/R	93	$15,514
2018	N/R	35	$4,881
2019	N/R	39	$2,988
2020	N/R	53	$3,421
2021	N/R	106	$6,305
2022	N/R	35	$4,181
2023	N/R	24	$1,960
2024	N/R	11	$169

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	68	68	$128
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	42	53	$109
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	53	53	$86
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	246	491	$70
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	102	117	$47

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Erleada	Apalutamide	84	2,520	$1,233,766
Brukinsa	Zanubrutinib	69	2,070	$826,959
Imbruvica	Ibrutinib	25	700	$418,666
Tagrisso	Osimertinib Mesylate	19	570	$368,655
Lenalidomide	Lenalidomide	29	770	$362,568

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$169

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	69	$1,528	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Gustavo P. Morel, MD?

Tedicare shows public-source Medicare data for Gustavo P. Morel, MD (NPI 1104855030), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Gustavo P. Morel, MD have ACO affiliation data?

Gustavo P. Morel, MD is shown with ACO affiliation data for OSF Healthcare System (MSSP, ACO ID A3289) and AdvantagePoint Health Alliance - Great Lakes, LLC (MSSP, ACO ID A4652).

What billing organization is linked to Gustavo P. Morel, MD?

Gustavo P. Morel, MD is linked to DICKINSON COUNTY HEALTHCARE SYSTEM (billing NPI 1891751186) in the available physician profile data.

Does Gustavo P. Morel, MD have Open Payments data?

Gustavo P. Morel, MD has 69 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.